Quick comparison
| Peptide | Class | Evidence | Status |
|---|---|---|---|
| Retatrutide | Triple GIP/GLP-1/glucagon receptor agonist peptide | Emerging | Investigational only, not FDA-approved, still in clinical trials |
| Tesamorelin | Growth hormone-releasing hormone (GHRH) analog peptide | Moderate | FDA-approved (Egrifta/Egrifta SV) only for HIV-associated lipodystrophy |
| CJC-1295 / Ipamorelin Stack | Growth hormone-releasing peptide stack | Limited | Not FDA-approved for weight loss, sold as research-use compounds |
| MOTS-C | Mitochondrial-derived peptide | Emerging | Not FDA-approved, sold as research-use-only |
The ranking
Retatrutide
Retatrutide is an investigational peptide that acts on three separate receptors at once (GIP, GLP-1, and glucagon), building on the same GLP-1 pathway used by approved drugs like semaglutide and tirzepatide but adding a third mechanism.
It is ranked first here because it is the furthest along in the “next generation” pipeline of obesity peptides and has drawn attention from clinics and industry coverage for reportedly strong human (Phase 2) weight-loss results, even though this research document’s sources treat it only superficially and do not themselves report specific trial figures.
Because it remains investigational, retatrutide is not something a consumer can obtain as an approved prescription today, and any specific efficacy numbers circulating publicly should be treated as preliminary human trial data, not confirmed real-world outcomes.
Strengths
- Combines three receptor targets (GIP/GLP-1/glucagon) rather than the one or two used by approved GLP-1 drugs
- Reported human (Phase 2) clinical trial data cited elsewhere as promising, though not detailed in this research set
Limitations
- Not FDA-approved, so it is not legally available as a prescription weight-loss treatment
- Human trial data is still early-stage (Phase 2/3), with long-term safety and effectiveness not yet established
- Best for
- Following next-generation weight-loss drug development, not for current use
- Evidence
- Emerging
- Status
- Investigational only, not FDA-approved, still in clinical trials
Tesamorelin
Tesamorelin is a synthetic growth hormone-releasing hormone analog and the only non-GLP-1 peptide with FDA-approved, human clinical trial evidence for reducing body fat. Its approval, however, is narrow: it is indicated specifically for reducing excess visceral and abdominal fat in adults with HIV-associated lipodystrophy, not for general weight management.
Per its FDA label, tesamorelin is explicitly described as weight-neutral, meaning it targets visceral fat redistribution rather than causing overall weight loss. This distinguishes it sharply from GLP-1 agonists like semaglutide or tirzepatide, which produce substantial total body weight loss in human trials.
It ranks here because it is the strongest human-evidence peptide outside the GLP-1 class, even though that evidence does not translate into a general-purpose weight-loss claim.
Strengths
- FDA-approved with human clinical trial data (in the HIV-associated lipodystrophy population)
- Clear regulatory and labeling clarity compared to unregulated "gray market" peptides
Limitations
- Not approved or evidenced for general weight loss; explicitly labeled weight-neutral
- Benefit is limited to a narrow, specific patient population (HIV-associated lipodystrophy)
- Best for
- Reducing excess visceral abdominal fat in HIV-associated lipodystrophy
- Evidence
- Moderate
- Status
- FDA-approved (Egrifta/Egrifta SV) only for HIV-associated lipodystrophy
CJC-1295 / Ipamorelin Stack
CJC-1295 and Ipamorelin are growth hormone secretagogues, meaning they stimulate the body’s own release of growth hormone rather than acting as direct fat-burning agents. Clinic-sourced sources describe them as supporting lean body composition, recovery, and sleep, which may indirectly aid body composition goals over time.
However, more conservative and higher-weighted sources explicitly state these peptides do not cause direct fat loss on their own, distinguishing them from GLP-1 medications that have robust human trial evidence.
This stack sits in a gray area: it is commonly discussed in wellness and clinic settings, but lacks the large-scale human weight-loss data that semaglutide or tirzepatide have.
Strengths
- Marketed and used by clinics to support lean muscle mass and recovery alongside training
- Associated with growth hormone pathways tied to sleep and body composition in clinic-sourced descriptions
Limitations
- No direct human clinical evidence that this stack causes fat loss on its own
- Higher-weighted, more skeptical sources explicitly separate these from "weight loss causing" peptides
- Often promoted uncritically on lower-quality commercial sources, with efficacy claims not corroborated elsewhere
- Best for
- Supporting lean body composition and recovery, not direct fat loss
- Evidence
- Limited
- Status
- Not FDA-approved for weight loss, sold as research-use compounds
MOTS-C
MOTS-C is a small peptide encoded by mitochondrial DNA that has drawn attention in metabolic research circles for its proposed role in regulating cellular energy use.
It is grouped among the gray-market compounds discussed alongside other unregulated peptides, meaning it lacks the large-scale human trials that back GLP-1 medications like semaglutide or tirzepatide.
The research reviewed here notes preclinical, metabolic-regulation signals but no human weight-loss trial data, so any fat-loss claim for MOTS-C remains unproven in people at this time.
Strengths
- Proposed metabolic-regulation activity noted in preclinical research
- Part of a broader mitochondrial-signaling pathway of ongoing scientific interest
Limitations
- No human weight-loss trial data currently exists for this compound
- Sold through unregulated channels with no FDA oversight, contamination risk, and unknown manufacturing conditions
- Lacks the large-scale human safety data available for approved GLP-1 medications
- Best for
- Curiosity about early-stage metabolic research, not weight loss
- Evidence
- Emerging
- Status
- Not FDA-approved, sold as research-use-only
How we picked
Each peptide here was ranked by weighing the strength and type of evidence behind it: whether human weight-loss data exists, whether that data comes from controlled trials or preclinical/animal studies, and whether any regulatory body has approved it for this use.
This ranking is not an endorsement of any compound, and with the exception of tesamorelin’s narrow FDA approval for HIV-associated lipodystrophy, none of these are FDA-approved for weight loss or fat reduction. Placement reflects evidence quality at time of writing, not safety, legality, or suitability for any individual.
Important safety note
Most compounds discussed here are sold as "research use only" and lack large-scale human safety data, meaning risks like contamination, impurities, or unknown long-term effects have not been ruled out. Retatrutide remains investigational and is not available outside clinical trials; CJC-1295, ipamorelin, and MOTS-c are unregulated in the consumer market. Anyone considering these should talk to a qualified clinician first; this is not medical advice and no dosing guidance is provided here.
Frequently asked questions
Is retatrutide available for people to use right now?
No. Retatrutide is investigational and still in clinical trials, meaning it has not been FDA-approved and is not legally available by prescription for weight loss.
Does tesamorelin work for general weight loss?
No. Tesamorelin is FDA-approved only to reduce visceral fat in adults with HIV-associated lipodystrophy, and its own label describes it as weight-neutral otherwise.
Will CJC-1295 or ipamorelin help me lose fat?
There is no direct evidence these cause fat loss on their own. They're associated with growth hormone release, recovery, and lean body composition support, not fat burning.
Is MOTS-c a proven weight-loss peptide?
Not yet. MOTS-c has shown metabolic-regulation signals in preclinical research, but no human weight-loss trial data currently exists.
Why isn't a GLP-1 drug like semaglutide on this list?
This ranking covers non-GLP-1 and emerging compounds specifically. GLP-1 medications have separate, much stronger clinical trial evidence and are addressed elsewhere in this guide.
Are any of these peptides safe to buy online without a prescription?
Buying unregulated peptides online carries real risks, including contamination and unknown manufacturing conditions, since they lack FDA oversight and large-scale human safety testing.
Should I try one of these instead of talking to a doctor?
No. None of these compounds are a substitute for medical guidance, and a qualified clinician should be involved before considering any of them.